Mr. Eugene Williams reports

PROMIS NEUROSCIENCES APPOINTS ACCOMPLISHED BIOPHARMACEUTICAL LEADER, DR. GAIL M. FARFEL, AS CHIEF EXECUTIVE OFFICER

Promis Neurosciences Inc. has appointed Gail M. Farfel, PhD, as chief executive officer, effective Sept. 19, 2022.

"The past 18 months have been transformative for Promis," stated Eugene Williams, Promis chairman and co-founder. "During this period, we achieved strong capital formation led by a prominent group of Boston-based investors, and with tremendous shareholder support, accomplished our goal of listing Promis on Nasdaq. We also have expanded and strengthened our board of directors, with the addition of three industry veterans as independent directors: Josh Mandel-Brehm, Dr. Maggie Shafmaster and Neil Warma. Our amyloid oligomer-selective lead therapeutic antibody candidate for Alzheimer's disease (AD), PMN310, is poised for IND [investigational new drug] submission by year-end and we have continued to expand our portfolio of antibody and therapeutic vaccine candidates targeting other neurodegenerative diseases. We have also continued to expand our strong management team, having added to the team earlier this year Dr. Larry Altstiel as chief medical officer and, in late 2021, Gavin Malenfant as chief operating officer. Perhaps the most important of these transformational accomplishments is bringing on Gail Farfel as CEO.

"Gail has a distinguished track record of accomplishments in both large pharma and biotech, and she has invaluable expertise in neurologic disease drug development. After an extensive search, we are confident that under Gail's leadership Promis can achieve its tremendous potential. Promis's board and management welcome her to the CEO role as we work to complete the transition to a clinical-stage, multiproduct, Nasdaq-listed company," added Mr. Williams.

"I am honoured and excited to take on the role of CEO at Promis," remarked Dr. Farfel. "There is a rapidly growing number of emerging companies in the neurology space, an area of tremendous growth, but I feel Promis is uniquely well positioned to make a meaningful contribution to the field. A very strong foundation has been built, anchored on a unique discovery platform, giving us the potential to advance what we believe to be differentiated products to address urgent unmet medical needs. I look forward to working with this impressive team and to providing my leadership as Promis seeks to become a clinical-phase biotechnology company with multiple development opportunities."

Dr. Farfel, PhD, is an accomplished pharma development and regulatory leader with over 25 years of experience in large and small pharma, including venture-backed and public companies. Dr. Farfel has a strong record of accomplishments in neuropsychiatric clinical development and global regulatory submissions, including multiple successful investigational new drug (IND), new drug application (NDA) and marketing authorization application (MAA) registrations, U.S. Food and Drug Administration (FDA) Advisory Committee experience, and three successful global first indications. On the business side, Dr. Farfel has played leadership roles in strategic planning, and commercial positioning for partnership and launch, initial public offerings, fundraising for publicly traded and private companies, and licensing and asset integration.

Prior to joining Promis, Gail served as executive vice-president and chief development officer of Zogenix Inc., where she delivered successful phase 3 programs in Dravet syndrome and Lennox-Gastaut syndrome (LGS), leading to approvals from FDA (Dravet and LGS) and European Medicines Agency (EMA) approval for Fintepla in 2020 and 2021. Further, while an executive at Zogenix, Dr. Farfel supported capital raises in excess of $700-million (U.S.), the acquisition of Modis Therapeutics, the alliance with Tevard Biosciences and the acquisition of Zogenix by UCB Pharma in March, 2022. In her earlier career, Dr. Farfel held positions of increasing responsibility at Smithkline Beecham, Pfizer, Novartis, G. Meredith Consulting and Marinus Pharmaceuticals. Dr. Farfel obtained her PhD in neuropsychopharmacology from the University of Chicago.

About Promis Neurosciences Inc.

Promis Neurosciences Inc. is a development stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The company's proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platforms -- Promis and Collective Coordinates -- to predict novel targets known as disease-specific epitopes on the molecular surface of misfolded proteins. Using this unique approach, the company is developing novel antibody therapeutics for AD, ALS and MSA. Promis is headquartered in Toronto, Ont., with offices in Cambridge, Mass. Promis is listed on Nasdaq and the Toronto Stock Exchange under the symbol PMN.

We seek Safe Harbor.